Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.

Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.

Analyst Comments Analyst EPS View Analyst PT Change

JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to OverweightNovember 9, 2017 4:37 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'November 8, 2017 11:54 AM Alnylam Pharma (ALNY) Tops Q3 EPS by 21cNovember 7, 2017 4:01 PM Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period ActivityNovember 7, 2017 4:00 PM Alnylam Pharma (ALNY) Initiates ENVISION Phase 3 Clinical Study with Givosiran to Treat AHPsNovember 7, 2017 7:09 AM Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)November 7, 2017 7:00 AM Medicines Co. (MDCO), Alnylam Pharmaceuticals (ALNY) Announce Initiation of Phase III Clinical Trials of InclisiranNovember 6, 2017 7:16 AM The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of InclisiranNovember 6, 2017 7:00 AM